(Q37799470)

23 August 2017

Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians (English)

1 reference

23 August 2017

1 reference

Marie Tran

1

1 reference

23 August 2017

Javad Tafreshi

series ordinal

2

1 reference

23 August 2017

Ramdas G Pai

series ordinal

3

1 reference

23 August 2017

11 October 2010

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

23 August 2017

1 reference

23 August 2017

15

1 reference

23 August 2017

4

1 reference

23 August 2017

326-337

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

23 August 2017

1 reference

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Cytochrome p450 and chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The chemically elegant proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Clinical pharmacology of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Pharmacokinetic drug interaction profiles of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Drug interaction between clopidogrel and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Pantoprazole: a new proton pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410369109

21 January 2018

Identifiers

DOI

10.1177/1074248410369109

1 reference

release_af4vzr3bcregjdtobjnhdlevey

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/af4vzr3bcregjdtobjnhdlevey

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference